Aptamer delivery of siRNAs to knockdown cancer
Judy Lieberman, MD, PhD, holds a Chair in Cellular and Molecular Medicine at Boston Children’s Hospital, is Professor of Pediatrics at Harvard Medical School and until recently was Chair of the Executive Committee of Immunology at Harvard Medical School. The Lieberman laboratory has been in the forefront of developing RNAi-based therapeutics and using RNAi for genome-wide screening. They were the first to show that siRNAs could be used to treat disease in vivo and to develop cell-targeted RNAs. They have developed strategies for cell-specific siRNAs that knockdown gene expression in vivo in T lymphocytes and cancer cells. Currently they are studying aptamer-siRNAs for immune therapy of epithelial cancers. They also investigate the role of microRNAs in regulating cell differentiation and cancer. Her laboratory also studies cytotoxic T lymphocytes and their role in immune protection from infection and cancer. They study the molecular pathways used by killer lymphocytes to induce programmed cell death of both mammalian cells and microbes and the mechanism responsible for inflammatory death (pyroptosis) triggered by innate immune recognition of invasive pathogens and danger signals. She has received numerous awards for her research on AIDS vaccines, immunology and cancer. She is a member of the American Academy of Arts and Sciences.
Program in Cellular and Molecular Medicine, Boston Children's Hospital Harvard Medical School 200 Longwood Avenue, Warren Alpert Building 255 Boston MA 02115, USA